Inappropriate long-term use of antipsychotic drugs is common among people with dementia living in specialized care units

Maria Gustafsson, Stig Karlsson and Hugo Lövheim

Abstract

Background: Antipsychotic drugs are widely used for the treatment of Behavioral and Psychological Symptoms of Dementia (BPSD), despite their limited efficacy and concerns about safety. The aim of this study was to describe antipsychotic drug therapy among people with dementia living in specialized care units in northern Sweden.

Methods: This study was conducted in 40 specialized care units in northern Sweden, with a total study population of 344 people with dementia. The study population was described in regard to antipsychotic drug use, ADL function, cognitive function and BPSD, using the Multi-Dimensional Dementia Assessment Scale (MDDAS). These data were collected at baseline and six months later. Detailed data about antipsychotic prescribing were collected from prescription records.

Results: This study showed that 132 persons (38%) in the study population used antipsychotic drugs at the start of the study. Of these, 52/132 (39%) had prescriptions that followed national guidelines with regard to dose and substance.

After six months, there were 111 of 132 persons left because of deaths and dropouts. Of these 111 people, 80 (72%) were still being treated with antipsychotics, 63/111 (57%) with the same dose. People who exhibited aggressive behavior (OR: 1.980, CI: 1.515-2.588), or passiveness (OR: 1.548, CI: 1.150-2.083), or had mild cognitive impairment (OR: 2.284 CI: 1.046-4.988), were at increased risk of being prescribed antipsychotics.

Conclusion: The prevalence of antipsychotic drug use among people with dementia living in specialized care units was high and inappropriate long-term use of antipsychotic drugs was common.

Keywords: Antipsychotic prescribing, Dementia, BPSD, Inappropriate prescribing, Aggression, Passiveness

Background

Dementia is a disorder that causes permanent and progressive impairment of cognitive functions such as memory and other cognitive abilities [1]. Behavioral and Psychological Symptoms of Dementia (BPSD) is the term applied to the various problems that complicate dementia and prevalence is high. It is estimated that up to 90% of patients with Alzheimer’s disease may present at least one BPSD during the course of the disease [2]. BPSD include behaviors such as aggression, screaming, restlessness, and also symptoms such as anxiety, hallucinations and depressive mood [3].

Antipsychotic drugs are widely used for the treatment of certain BPSDs; one study showed that 40% of elderly people with cognitive impairment living in group dwellings took antipsychotic drugs [4]. However, antipsychotic drugs have demonstrated only limited efficacy in the treatment of BPSD. A systematic review found that first generation antipsychotics had little efficacy at best, and that the benefits may not outweigh the risk of side effects [5]. The same review showed that olanzapine and risperidone had a modest, statistically significant efficacy with minimal adverse effects at lower doses [5]. However, in another study, adverse effects offset the clinical
benefit of second generation antipsychotics for the treatment of BPSD [6].

Older people tend to experience side-effects more frequently and with greater severity than younger people, and antipsychotic drugs have a number of side-effects. First generation antipsychotics are associated with a high prevalence of extrapyramidal side-effects (EPS) and tardive dyskinesia due to their high affinity for D2-receptors [7]. Second generation antipsychotics have a different receptor-binding profile. Since they interact with both D2 and 5HT2-receptors, they cause EPS to a lesser extent [8]. The use of antipsychotic drugs appears to be associated with accelerated cognitive decline in people with Alzheimer’s disease; treatment with haloperidol over 6–8 weeks was associated with a decline in cognition measured using the Mini-Mental State Examination (MMSE) [9]. However, one study showed that the MMSE score did not worsen after treatment with risperidone among people with dementia [10], which might be due to the lack of anticholinergic activity of risperidone [11]. All antipsychotics seem to cause metabolic side-effects. However, it appears that second generation antipsychotics are worse in this regard, even if there is variation among substances in this group [12].

Second generation antipsychotics have also been associated with an increased risk of cerebrovascular events and increased mortality, and first generation antipsychotics seem to carry the same risk [13,14].

Support for the long-term use of antipsychotics in this patient population is limited. There is some evidence favoring short-term use, [1,15] even if it is considered an option of last resort. Even short-term use of antipsychotics increases the risk of serious adverse events [16]. According to the Swedish Medical Products Agency, the dose should initially be low and then titrated upwards and treatment should be time-limited and regularly reviewed [1]. Only two recent studies have described long-term antipsychotic treatment among people with dementia [17,18] and both found relatively high rates of long-term treatment. There is still a need for detailed study of the long-term use of antipsychotic in this population. The aim of this retrospective study was to describe the prevalence, associated factors and long-term use of antipsychotic drugs among people with dementia living in specialized care units.

Methods

Subjects and settings

The study population for this project has previously been used in a research study concerning use of physical restraint [19]. This was an intervention study conducted in 2005-2006, which included 40 specialized care units (353 people) in nine communities in northern Sweden. These units are designed to provide care for six to eight persons with dementia in homelike environments. All specialized care units in these communities were inventoried, i.e. 99 units were contacted - and units with the highest prevalence of physical restraint use (≥20%) were selected. In the present study, 9 people were excluded due to incomplete data. The study was approved by the Regional Ethical Review Board in Umeå (registration number 02-105).

Procedures

Data were collected by means of a questionnaire completed by care unit staff, the Multi-Dimensional Dementia Assessment Scale (MDDAS) [20]. The MDDAS has good intra- and inter-rater reliability [20]. This instrument includes assessment of the level of functioning in activities of daily living (ADL), cognition and behavioral and psychological symptoms. ADL function score ranges from 4-24, where a higher score indicates greater ADL independence. This score is based on the person’s ability to cope with hygiene, dressing, eating and bladder and bowel control. Cognitive function was measured using an assessment scale developed by Gottfries and Gottfries [21]. This scale ranges from 0-27 points and a score of less than 24 is considered to indicate cognitive impairment, correlating with a sensitivity of 90% and a specificity of 91% to the usual cut-off point of the MMSE (24/30) [21,22]. The scale is further subdivided into three groups - mild cognitive impairment (16-23), moderate cognitive impairment (8-15) and severe cognitive impairment (0-7). The MDDAS contains 25 behavioral items and 14 psychological symptom items. Each item is rated on a three-point scale indicating that the symptom was present at least once a day, once a week, or never during the observation period of one week. These variables are dichotomized between at least once a week and less than once a week in the present study.

All persons’ prescription records were collected at the start of the study and six months later. The majority of people dispensing service where the used an automated multidose dispensing service where the persons’ drugs are dispensed in one dose unit bag for each dose occasion.

The prescription records were searched to identify those people from the study population treated with antipsychotic drugs. All people were listed by age, sex, and treatment with antidepressants (N06A), anxiolytics, hypnotics and sedatives (N05B&C), anti-dementia drugs (N06D), and antipsychotics (N05A). The WHO ATC (Anatomical Therapeutic Chemical Index) classification system was used.

Information about dose and type of antipsychotic drugs was collected, and also indication for treatment when this was reported in the prescription records. These indications are written by the prescribing physicians to describe
for the patient and nursing staff why the patient is prescribed the drug. Also, the pharmacy uses the indication to check the appropriateness of drug choice and dose.

Lithium (N05AN01) was not included since it differs from antipsychotics regarding both mechanism of action and use. Pro re nata (PRN) drugs were also not included, as information was lacking on the actual use of these drugs, and furthermore very few people used PRN antipsychotics.

To be able to compare antipsychotic doses between baseline and follow-up, we calculated all antipsychotics in haloperidol equivalents. Recommendations concerning antipsychotic use vary slightly in different guidelines [1,15]. Since this study was conducted in Sweden, we used the guidelines from the Swedish Medical Products Agency to evaluate the appropriate use of antipsychotics [1]. These guidelines state that risperidone is the only antipsychotic drug that is labeled for use in combating BPSD in Sweden, and the recommended dose is ≤1.5 mg daily. According to the same guidelines, the indications that justify the prescribing of antipsychotic drugs in people with BPSD are psychotic symptoms and aggressive behavior that causes suffering or potential danger for the person or others.

Statistics and calculations
People who did and did not take antipsychotics were compared using the Pearson chi-square test and t-test for dichotomous and continuous variables respectively. SPSS 18 for MacOS X was used for data handling and statistical calculations. A p-value of < 0.05 was considered statistically significant. A multiple logistic regression model was constructed to find factors independently associated with antipsychotic drug use. The behavioral and the psychological symptom items of the MDDAS were grouped and weighted (in each group every symptom was multiplied with the calculated factor loading and then added with next symptom) according to a factor analysis previously described by Lövheim et al [23]. The factors were then normalized and included in a logistic regression model which also included age, sex and level of cognitive impairment. As many of the behavioral and psychological symptoms correlated strongly, the behaviors and symptoms were tested in the regression model in a stepwise procedure, where the behavior that had the strongest bivariate correlation (aggressive behavior) was included first, and all other behaviors and symptoms were included subsequently one by one to see if any of them contributed independently. These behaviors and factors, apart from aggressive behavior, were: wandering behavior, restless behavior, verbally disruptive/attention-seeking behavior, passiveness, hallucinatory symptoms, depressive symptoms, disoriented symptoms and regressive/inappropriate behavior. Ultimately, all significant behaviors and symptoms were included in a final model.

Survival among people who were treated with antipsychotic drugs at the start of the study was compared with those who were not treated with antipsychotics, using a Cox regression, also including age, sex and level of cognitive impairment.

Results
The study population comprised 344 people with dementia whose characteristics are presented in Table 1. One hundred and thirty-two (38%) of these people used antipsychotic drugs at the start of the study; 118 people were prescribed one antipsychotic drug, 13 took two, and 1 person had three antipsychotic drugs prescribed concomitantly. Ninety prescriptions were for second generation antipsychotics, and 57 for first generation antipsychotics. There were no associations between antipsychotic drug use and antidepressant drug use, or between antipsychotic drug use and anti-dementia drug use. However, there was an association between antipsychotic drug use and anxiolytic, hypnotic and sedative drug use, as shown in Table 1. An association was found between antipsychotic drug prescribing and age, but no difference between men and women.

The multiple logistic regression analysis showed that those who exhibited an aggressive behavior, or passiveness, were younger or had mild cognitive impairment as compared to severe cognitive impairment, were at increased risk of being prescribed an antipsychotic drug (Table 2).

After six months, 111 people remained to be evaluated of those who were treated with antipsychotics at baseline (7 dropouts, 14 deceased), as presented in Figure 1. Of these 111 people, 80 (72%) were still being treated with antipsychotics, 63 of these with the same dose. Seventy-eight people of 80 were taking the same antipsychotics as before. Of those who were not treated with antipsychotics at baseline, 10 people were receiving antipsychotics at the 6-month follow-up. After six months, 31 persons had ended their treatment with antipsychotics. The mean age of this group was 83.1, compared to 80.0 among those who still were using antipsychotics after six months (80 persons). However, this difference was not significant. No significant differences were seen concerning ADL, cognitive score or sex.

The mortality analysis showed no difference in mortality between those who received antipsychotics at the start of the study and those who did not (OR 0.69, CI 0.36-1.32, p-value 0.26).

At the start of the study, 132 people were prescribed antipsychotic drugs; 62 of these received risperidone, the only antipsychotic drug that is labeled for use in BPSD in Sweden, as shown in Table 3. Of these 62, 52 received the recommended dose, i.e. ≤1.5 mg daily. Hence, 52/132 (39%) received both recommended antipsychotic
drug and the recommended dose, assuming that antipsychotics were used solely for the treatment of BPSD.

The indications for prescribing antipsychotic drugs to this patient group are listed in Table 4. The most common indication was “treatment of disturbed and restless behavior/sedative”. No indication was listed for 19 prescriptions. After six months, ten people who did not receive antipsychotics at baseline, had been started on antipsychotic drugs. Of these ten, one received risperidone and nine people received other antipsychotics. The dose of risperidone of this one person, however, was higher than the recommended dose. The most common indication was “treatment of disturbed and restless behavior/sedative”, similar to those having antipsychotics at study start.

**Discussion**

This study showed that many people with dementia who lived in specialized care units were prescribed antipsychotic drugs for long periods. It seems that in most cases the doses were probably not regularly adjusted; a majority of the people appeared to be on stable doses for six months or possibly longer. There were also few people in our study who had been prescribed the drugs in agreement with current recommendations concerning dosage and drug choice. The study showed that people who exhibited aggressive behavior, or passiveness, or had a higher cognitive score, were at increased risk of being prescribed antipsychotics. Those who received antipsychotics were also significantly younger. We found no difference between men and women concerning antipsychotic drug use.

Furthermore, the use of more than one psychotropic drug seemed to be common, 72/344 had anxiolytics/hypnotics/sedatives and an antipsychotic drug prescribed simultaneously and 73/344 had antidepressants and an antipsychotic drug prescribed simultaneously. In addition, 14 persons had more than one antipsychotic drug prescribed.

The present results are in accordance with previous studies. One study found that people received psychotropic drugs over at least one year despite uncertainty about symptom improvement and another study showed that most antipsychotic prescriptions remained unchanged over a six-month period [17,18]. In the present study, 63/111 (57%) received exactly the same antipsychotic dose after six months. The high prevalence of long-term use is not in line with current recommendations which emphasize that treatment should be time-limited and regularly reviewed [15]. Selbæk *et al* also demonstrated that most symptoms show an intermittent course which does not support long-term treatment with antipsychotics [18]. O’Connor *et al* discuss the fact that the person’s symptoms are classified as present when in reality they occur only occasionally [17]. These findings stress the importance of reviewing antipsychotic use regularly to ensure that the indication remains. One study also showed that dementia persons’ symptoms

| Table 1 Characteristics of study population and comparison between people with and without antipsychotics |
|---------------------------------------------------------------|
| **With AP** | **Without AP** | **Total** | **p-value** |
| Cases, n (%) | 132 (38.4) | 212 (61.6) | 344 | 0.62 |
| Women, n (%) | 92 (69.7) | 153 (72.2) | 245 (71.2) | 0.02 |
| Mean age ± SD | 80.9 ± 8.6 | 82.9 ± 7.2 | 82.1 ± 7.8 | 0.02 |
| ADL score (4-24) mean ± SD | 11.9 ± 5.2 | 12.2 ± 5.4 | 12.1 ± 5.3 | 0.63 |
| Cognitive score (0-27) mean ± SD | 10.6 ± 7.4 | 10.0 ± 7.2 | 10.2 ± 7.3 | 0.47 |
| Antidepressant (N06A) use, n (%) | 73 (55.3) | 107 (50.5) | 180 (52.3) | 0.38 |
| Anxiolytics, hypnotics and sedatives (N05B&C) use, n (%) | 72 (54.5) | 84 (39.6) | 156 (45.3) | 0.007 |
| Anxiolytics (N05B) use, n (%) | 28 (21.2) | 18 (8.5) | 46 (13.4) | 0.001 |
| Hypnotics and sedatives (N05C) use, n (%) | 63 (47.7) | 76 (35.8) | 139 (40.4) | 0.029 |
| Anti-dementia drugs (N06D) use, n (%) | 26 (19.7) | 45 (21.2) | 71 (20.6) | 0.733 |

SD= Standard Deviation, ADL= activities of daily living, AP= Antipsychotic drug.

| Table 2 Multiple logistic regression of antipsychotic drug use |
|---------------------------------------------------------------|
| **Odds Ratio** | **95% confidence interval** | **p-value** |
| Male sex | 0.969 | 0.546-1.719 | 0.913 |
| Higher age | 0.958 | 0.924-0.993 | 0.018 |
| Moderate cognitive impairmenta | 1.802 | 0.973-3.338 | 0.061 |
| Mild cognitive impairmentb | 2.284 | 1.046-4.988 | 0.038 |
| Aggressive behavior | 1.980 | 1.515-2.588 | <0.001 |
| Passiveness | 1.548 | 1.150-2.083 | 0.004 |

Model Cox and Snell R²: 0.129, concordance between observed and predicted value: 67.6%. *Cognitive score ranges from 0-27 points and a score of less than 24 is considered to indicate cognitive impairment. The scale is subdivided into three groups, 0-7 (severe cognitive impairment), 8-15 (moderate cognitive impairment) and 16-23 (mild cognitive impairment). Severe cognitive impairment is reference category.*
remain stable when they are withdrawn from first generation antipsychotics, and another study found that people actually improved when second generation antipsychotics were withdrawn [25,26].

Furthermore, the indications that were given for the prescriptions in our study were not in line with the recommendations. By far the most common indication in this study was “treatment of disturbed and restless behavior/sedative”, and this is not an approved indication, according to the guidelines. Some indications were doubtful and in many cases were missing. However, these results should be interpreted with caution since the indications often overlap and the way of expression might differ between physicians. The choice of antipsychotic drugs among prescribers in this study was somewhat surprising considering that the second generation antipsychotics risperidone and olanzapine seem to have the best evidence-base for effectiveness, compared to placebo for physical aggression, agitation and psychosis [27,28]. Risperidone and haloperidol were the most commonly used antipsychotics in our study, which is to be expected. Haloperidol has little anticholinergic activity and was by many considered the most preferable antipsychotic to people with dementia before the introduction of the second generation antipsychotics. An established treatment tradition might possibly have

![Flow chart of participants from baseline to 6-month follow-up.](image)

**Table 3 Characteristics of antipsychotic drugs at the start of the study**

| Drug            | n     | Percent (%) of prescribings | Dose, mean ± SD | Median Dose (mg) | Range (mg) | Mean Dose (mg) | Halo-peridol equivalents | 1 mg equivalent doses¹ |
|-----------------|-------|----------------------------|-----------------|-----------------|------------|----------------|--------------------------|------------------------|
| **First generation AP** |       |                            |                 |                 |            |                |                          |                        |
| Haloperidol     | 25    | 17.0                       | 2.1±3.1         | 1.0             | 0.5-16     | 2.1            | 1                         |                        |
| Levomepromazine | 12    | 8.1                        | 19.6±15.6       | 15.0            | 5-50       | 0.4            | 50                        |                        |
| Zuclopenthixol  | 6     | 4.1                        | 3.7±2.0         | 3.0             | 2-6        | 0.7            | 5                         |                        |
| Dizyrazine      | 5     | 3.4                        | 32.0±38.3       | 20.0            | 10-100     | 1.1            | 30                        |                        |
| Melperone       | 4     | 2.7                        | 33.8±11.1       | 30.0            | 25-50      | 0.8            | 40                        |                        |
| Perphenazine    | 4     | 2.7                        | 7.8±5.9         | 6.0             | 3-16       | 1.9            | 4                         |                        |
| Chlorpromazine  | 1     | 0.7                        | 100.0           |                 |            | 2.0            | 50                        |                        |
| **Second generation AP** |       |                            |                 |                 |            |                |                          |                        |
| Risperidone     | 62    | 42.2                       | 1.1±1.1         | 0.8             | 0.25-8     | 1.1            | 1                         |                        |
| Olanzapine      | 18    | 12.2                       | 6.9±5.1         | 5.0             | 3-20       | 2.3            | 3                         |                        |
| Ziprasidone     | 6     | 4.1                        | 60.0±31.0       | 50.0            | 40-120     | 1.5            | 40                        |                        |
| Clozapine       | 3     | 2.0                        | 216.7±332.0     | 25.0            | 25-600     | 4.3            | 50                        |                        |
| Quetiapine      | 1     | 0.7                        | 50.0            |                 |            | 0.3            | 150                       |                        |

Number of prescriptions=147, number of persons taking AP=132, AP=antipsychotic drugs. ¹[24].
positive efficacy in various studies [33-39]. Among anti-antine, cholinesterase inhibitors and SSRI have shown

delayed the switch to second generation drugs and explain why many old people with dementia were still treated
with haloperidol in 2006. Haloperidol has some efficacy against behavioral problems in higher doses, but its use is limited by side-effects [1]. Risperidone on the other hand is a well-tolerated alternative among people with dementia in lower doses [29] and is, as stated above, the only antipsychotic drug that is labeled for use in BPSD in Sweden. The proportion of people with antipsychotics treated with second generation drugs will probably continue to increase [30].

A more unexpected finding was the fact that these two drugs did not account for a larger share of the antipsychotic prescriptions. Many older first generation antipsychotics and also some of the newest second generation antipsychotics were used to treat BPSD in this patient group. The reason prescribing physicians deviated from current guidelines is unclear. This study was conducted in 2005 and 2006, i.e. 2-3 years before the guideline was issued. Possibly, the prescription may have changed due to new recommendations, however, we still find it relevant to compare the treatment with what is now considered to be appropriate medication.

However, there are other possibilities for treating BPSD in persons with dementia. Primarily, non-pharmacological approaches are recommended, such as investigation /survey of symptoms, possible causes and triggering moments. It is also important to review current pharmacological treatment and consider discontinuation of drugs with potentially adverse effects on the central nervous system and finally, to optimize the care environment and treatment [1,31]. For example, it has been shown that music, physical exercise and recreation might have some effect considering psychological symptoms in people with dementia [32]. When it comes to pharmacological treatment, memantine, cholinesterase inhibitors and SSRI have shown positive efficacy in various studies [33-39]. Among antipsychotics more frequently, might have contributed to our results considering mortality and antipsychotics. We did not know the length of exposure to antipsychotics, only that a person was treated with an antipsychotic drug at the start of the study and this have possibly influenced the results. Also, in this study we lacked information about the prevalence of cerebrovascular diseases and other co-morbidities that might have impacted on mortality.

In this study we have been able to describe in detail long-term use of antipsychotics among people with dementia. The registration of drugs and doses in the present study was of high quality. We can also assume

| Table 4 Indications for antipsychotic treatment at the start of the study |
|--------------------------------------------------|
| Treatment of disturbed and restless behavior/sedative n (%) | 67 (42.9) |
| Delusions/hallucinations/paranoia n (%) | 16 (10.3) |
| Treatment of mood/irritability/anxiety, n (%) | 14 (9.0) |
| Treatment of aggression, n (%) | 13 (8.3) |
| Treatment of insomnia, n (%) | 12 (7.7) |
| Treatment of psychosis, n (%) | 7 (4.5) |
| Treatment of confusion, n (%) | 3 (1.9) |
| To combat behavioral disorders/BPSD, n (%) | 2 (1.3) |
| Other indications, n (%) | 3 (1.9) |
| No indication, n (%) | 19 (12.2) |

Indication at baseline. Number of prescriptions=147, number of persons taking antipsychotics=132. The number of indications (156) is higher since there were sometimes more than one indication per prescription.
that compliance was high since the vast majority of patients used an automated dose dispensing system.

The study also has some methodological limitations. The selection of specialized care units was not random but based on the prevalence of physical restraint use. It could be that people in these homes have severe problems with BPSD and, therefore, receive long-term treatment to a greater extent. In the physical restraint study [19] there was no difference in antipsychotic use within groups or between groups at baseline and after six months, but we have not been able to compare data with non-selected units since we do not have that information. However, the proportion of those who were on antipsychotic drugs does not appear to differ from those found in other studies [4]. We believe that this does not affect the main results of the study, but it should be borne in mind when interpreting the results.

Data were registered at the start of the study and six months later, but what happened between those times is not known, except for mortality. We do not know the duration of antipsychotic treatment at the time of recruitment into the study, and we also do not know if any attempts of dose reduction or attempts of non-pharmacological treatment of BPSD have been made. Further, we do not know the background or other diseases of the participants, and we lack information about adverse effects of antipsychotics e.g. extrapyramidal effects or falls.

In our study, there could possibly have been reasons other than BPSD for prescribing antipsychotics. Some people might have schizophrenia or other chronic psychotic illnesses where recommendations about dose and substance differ from recommendations among people with dementia. This might, to some extent, explain the use of other antipsychotic drugs or higher doses.

Still, the reason for prescribing antipsychotics is probably related to BPSD in the vast majority of cases, among old people with dementia living in specialized care units.

Conclusion

The prevalence of antipsychotic drug use among people with dementia living in specialized care units was high and inappropriate long-term use of antipsychotic drugs was common. The prescriptions were often not in agreement with current recommendations.

Competing interests
The authors declare no conflict of interests.

Authors’ contributions
SK was responsible for the study concept, design and acquisition of subjects. MG reviewed the data for a second time and HL made the statistical analysis. MG and HL analyzed and interpreted the data and prepared the manuscript. All authors critically revised the manuscript, added their comments and approved the final version.

Acknowledgements
This study was supported financially by grants from the Swedish Academy of Pharmaceutical Sciences, the Lions Research Foundation for Age-Related Diseases, Swedish Brain Power, the Swedish Dementia Association and the County Council of Västerbotten.

Author details
1Maria Gustafsson, Department of Pharmacology and Clinical Neuroscience, Umeå University, 901 85, Umeå, Sweden. 2Stig Karlsson, Department of Nursing, Umeå University, Umeå, Sweden. 3Hugo Lövheim, Department of Community Medicine and Rehabilitation, Geriatric Medicine, Umeå University, Umeå, Sweden.

Received: 17 September 2012 Accepted: 4 February 2013
Published: 8 February 2013

References
1. Läkemedelsverket. Betecknandeäggs- och psykiska symptom vid demenssjukdom – BPSD. Information from the Medical Product Agency. Retrieved June 10, 2012 from http://www.lakemedelsverket.se/upload/halsoc- och-sjukskad/behandlingsrekommendationer/BPSD_bakgrund_webb.pdf.
2. Liporiot R, Pedone C, Coronel A: Antipsychotics for the treatment of Behavioral and Psychological Symptoms of Dementia (BPSD). Current Neuropharmacology 2008, 6:117–124.
3. Cerqueira J, Lagarto L, Mukaetova-Ladinska EB: Behavioral and psychological symptoms of dementia. Frontiers in Neurology 2012, 3:73.
4. Lövheim H, Sandman PO, Kallin K, Karlsson S, Gustafson Y: Relationship between antipsychotic drug use and behavioral and psychological symptoms of dementia in old people with cognitive impairment living in geriatric care. Int Psychogeriatr 2006, 18:713–26.
5. Sink KM, Holden KF, Yaffe K: Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. J Am Med Assoc 2005, 293:696–698.
6. Schneider LS, Tarot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Blackwell DL, Weintraub D, Lieberman JA, CATIE-AD Study Group: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 2006, 355:1525–1538.
7. Neil W, Curran S, Watts J: Antipsychotic prescribing in older people. Age Ageing 2003, 32:475–483.
8. Gareri P, De Fazio P, Stillo MA, Ferreri G, De Sarro G: Conventional and atypical antipsychotics in the elderly: a review. Clin Drug Invest 2003, 23:287–322.
9. Gareri P, Cortoneo A, Marchisio U, Curcio M, De Sarro G: Risperidone in the treatment of behavioral disorders in elderly patients with dementia. Arch Gerontol Geriatr Suppl 2001, 7:73–82.
10. Gareri P, De Fazio P, De Fazio S, Marigliano N, Ferreri Ibbadia G, De Sarro G: Adverse effects of atypical antipsychotics in the elderly: a review. Drugs Aging 2006, 23:937–56.
11. Devanand DP, Sackheim HA, Brown RP, Mayeux R: A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer’s disease. Arch Neurol 1989, 46:854–857.
12. Meikerson KI, Dahl ML, Hulting AL: Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism. Psychopharmacology 2004, 175:1–6.
13. Schneider LS, Dagerman KS, Insel R: Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. J Am Med Assoc 2005, 294:1934–1943.
14. Gill SS, Bronskill SE, Normand SL, Anderson GM, Sylvia K, Lunn K, Bell CM, Lee PE, Fischer HD, Herrmann N, Gurwitz JH, Rochon PA: Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007, 146:775–786.
17. O’Connor DW, Griffith J, McSweeney K: Changes to psychotropic medications in the six months after admission to nursing homes in Melbourne, Australia. Int Psychogeriatr 2010, 22:1149–53.

18. Selbak G, Kirkevold Ø, Engedal K: The course of psychiatric and behavioural symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes a 12-month follow-up study. Am J Geriatr Psychiatry 2008, 16:525–36.

19. Pellfolk TJ, Gustafson Y, Bucht G, Karlsson S: A descriptive study of 3600 institutionalized patients in the county of Vasterbotten, Sweden. Compr Gerontol A 1988; 2:120–132.

20. Sandman PO, Adolfsson R, Norberg A, Nyström L, Winblad B: Long-term care of the elderly. A descriptive study of 3600 institutionalized patients in the county of Vasterbotten, Sweden. Compr Gerontol A 1988; 2:120–132.

21. Adolfsson R, Gottfries CG, Nyström L, Winblad B: Prevalence of dementia disorder in institutionalized Swedish old people. The work load imposed by caring for these patients. Acta Psychiatr Scand 1981, 63:225–244.

22. Finkel SI, Kozma C, Long S, Greenspan A, Mahmoud R, Baser O, Engelhart L: Behavorial and psychological symptoms of dementia in relation to level of cognitive impairment. Int Psychogeriatr 2008, 20:777–89.

23. Eriksson L, Pelling H: Psychosomatic (in English: Psychosess). In Läkemedelsboken. 2005/2006. Stockholm: Apoteket AB, 2005:806–814.

24. Cohen-Mansfield J, Lipson S, Werner P, Billig N, Taylor L, Wooley R: Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. Arch Intern Med 1999, 159:1733–1740.

25. Rutsch S, Straand J, Nygaard HA, Aarsland D: Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study – The Bergen District Nursing Home Study (BEDNURS). Int J Geriatr Psychiatry 2008, 23:889–895.

26. Brodsky H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman F: A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003, 64:134–143.

27. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitra SJ, Kadam DL, Sanger TM, Feldman PO, Tollefson GD, Breier A: The HGEU Study Group: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2000, 57:968–76.

28. Garee P, Cotroneo A, Lacava R, Seminara G, Marigliano N, Loiacono A, De Sarro G: Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD). Arch Gerontol Geriatr Suppl 2004, 9:207–15.

29. Lövheim H, Gustafson Y, Karlsson S, Sandman PO: Comparison of behavioral and psychological symptoms of dementia and psychotropic drug treatments among old people in geriatric care in 2000 and 2007. Int Psychogeriatr 2011, 23:1616–22.

30. Finkel SI, Ballard C, Juszczak E, James I, Alder N, Jacobsy R, Howard R: Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. Br Med J 2006, 332:756–61.

31. O’Connor DW, Ames D, Gardner B, King M: Psychosocial treatments of psychological symptoms in dementia: a systematic review of reports meeting quality standards. Int Psychogeriatr 2009, 21:341–251.

32. Maidment ID, Fox CG, Boustani M, Rodríguez J, Brown RC, Katona CL: Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother 2008, 42:2–38.

33. Gauthier S, Cummings J, Ballard C, Brodaty H, Grossberg G, Robert P, Lyketsos C: Management of behavioral problems in Alzheimer’s disease. Int Psychogeriatr 2010, 22:346–72.

34. Pollock BG, Mulsant BH, Rosen J, Sweet RA, Mazumdar S, Bharucha A, Marin R, Jacob NJ, Huber KA, Kastang KB, Chew ML: Comparison of clozapram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002, 159:460–465.

35. Nyth AL, Gottfries CG: The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic Multicentre study. Br J Psychiatry 1990, 157:294–301.

36. Lanctôt KL, Herrmann N, van Reekum R, Eryavec G, Naranjo CA: Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer’s disease. Int J Geriatr Psychiatry 2002, 17:531–541.

37. Pollock BG, Mulsant BH, Rosen J, Mazumdar S, Blakesley RE, Houck PR, Huber KA: A double-blind comparison of Citalopram and Risperidone for the Treatment of Behavioral and Psychotic Symptoms Associated With Dementia. Am J Geriatr Psychiatry 2007, 15:942–52.

38. Finkel SI, Kozma C, Long S, Greenspan A, Mahmoud R, Baser O, Engelhart L: Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr 2005, 17:517–29.